NCT06100991

CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: CorEvitas · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200 subjects and 75 clinical sites in North America will be recruited to participate with no defined upper limit for either target

Detailed description

The objective of the registry is to obtain information on the treatment patterns, disease activity progression, and the development of comorbidities and adverse events in a cohort of patients with GPP. Data collected will be used to better characterize the natural history and longitudinal trajectory of the disease. This will be done through the standardized data collection including validated patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), the active evaluation of prevalent and incident comorbidities and adverse events, and the recording of medication utilization patterns. Personal information is also collected from each consenting registry subject allowing for linkages to other public or private clinical and administrative databases, as well as to databases maintained by organizations focused on the care and treatment of GPP for the purposes of clinical, market, or outcomes research. This provides an opportunity to evaluate other aspects of the disease and its treatment, including but not limited to clinical and drug cost-effectiveness, health care resource utilization, and subject adherence.

Conditions

• Generalized Pustular Psoriasis

Timeline

• Start date: 2023-09-19
• Primary completion: 2099-12-01
• Completion: 2099-12-01
• First posted: 2023-10-25
• Last updated: 2026-02-09

Locations

1 site across 1 country: United States